newsfilter
← Latest News
GlobeNewswire·

TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19

1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention option SOUTH SAN FRANCISCO, Calif. and TAIPEI,...